The clinical research of transurethral diode laser en bloc resection combined with gemcitabine intravesical chemotherapy for non-muscle invasive bladder tumor

Abstract

Objectives To evaluate the safety and efficacy of transurethral diode laser en bloc resection combined with gemcitabine intravesical chemotherapy for the treatment of non-muscle invasive bladder tumor. Methods From July 2014 to July 2015, clinical data of 62 patients with non-muscle invasive bladder tumor were retrospectively analyzed.All patients received transurethral diode laser en bloc resection and gemcitabine intravesical chemotherapy.The operative time, intraoperative blood loss, incidence of operative complications, bladder irrigation time, days for urethral catheterization, duration of hospitalization after surgery and recurrence were recorded. Results The mean operative time was (30.5±12.8)min with less amount of blood loss, and the obturator nerve reflex, perforation, water intoxication, urinary leakage and secondary hemorrhage did not occur.The mean time of bladder irrigating was(6.15±2.33)h, the mean time of catheterization was (7.33±1.54)d and the mean time of hospitalization after surgery was(8.21±1.26)d. Patients were followed up for 6 to 18 months, with 3 cases of ectopic recurrence. Conclusions Transurethral diode laser en bloc resection combined with gemcitabine intravesical chemotherapy for the treatment of non-muscle invasive bladder tumor is safe and effective.The operation can provide accurate tumor classification and staging information, and it is worthy of wide clinical application. Key words: Urinary Bladder Neoplasms; Cystectomy; Lasers